Meclozine promotes longitudinal skeletal growth in transgenic mice with achondroplasia carrying a gain-of-function mutation in the fgfr3 gene

Endocrinology (United States)

Volumn 156, Issue 2, 2015, Pages 548-554

  Matsushita, Masaki ^a   Hasegawa, Satoru ^a   Kitoh, Hiroshi ^a   Mori, Kensaku ^b   Ohkawara, Bisei ^c   Yasoda, Akihiro ^c   Masuda, Akio ^b   Ishiguro, Naoki ^a   Ohno, Kinji ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; MECLOZINE; FGFR3 PROTEIN, MOUSE; HISTAMINE H1 RECEPTOR ANTAGONIST;

ACHONDROPLASIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY HEIGHT; BONE DEVELOPMENT; BONE GROWTH; BONE LENGTH; BONE MASS; BONE MATURATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; EMBRYO; EMBRYO DEVELOPMENT; FEMALE; FEMUR; FORAMEN MAGNUM; GAIN OF FUNCTION MUTATION; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RADIUS; SHORT STATURE; SKULL; TIBIA; TRANSGENIC MOUSE; ULNA; ANIMAL; BLOOD; DRUG EFFECTS; GENETICS; GROWTH, DEVELOPMENT AND AGING; IN VITRO STUDY; MUTATION; RANDOMIZATION;

ACHONDROPLASIA; ANIMALS; BONE DEVELOPMENT; FEMALE; HISTAMINE H1 ANTAGONISTS; IN VITRO TECHNIQUES; MALE; MECLIZINE; MICE, TRANSGENIC; MUTATION; RANDOM ALLOCATION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; TIBIA;

EID: 84921641417     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-1914     Document Type: Article

References (24)

1. Rousseau F, Bonaventure J, Legeai-Mallet L, et al. Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature. 1994;371:252-254
2. Shiang R, Thompson LM, Zhu YZ, et al. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell. 1994;78:335-342
3. Prinos P, Costa T, Sommer A, Kilpatrick MW, Tsipouras P. A commonFGFR3gene mutation in hypochondroplasia.HumMol Genet. 1995;4:2097-2101
4. Tavormina PL, Bellus GA, Webster MK, et al. A novel skeletal dysplasia with Developmental Delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene. Am J Hum Genet. 1999;64:722-731
5. Tavormina PL, Shiang R, Thompson LM, et al. Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nat Genet. 1995;9:321-328
6. ToyDemir RM, Brassington AE, Bayrak-ToyDemir P, et al. A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome. Am J Hum Genet. 2006;79:935-941
7. Waller DK, Correa A, Vo TM, et al. The population-based prevalence of achondroplasia and thanatophoric dysplasia in selected regions of the US. Am J Med Genet A. 2008;146A:2385-2389
8. Horton WA, Hall JG, Hecht JT. Achondroplasia. Lancet. 2007; 370:162-172
9. Horton WA, Hecht JT, Hood OJ, Marshall RN, Moore WV, Hollowell JG. Growth hormone therapy in achondroplasia. Am J Med Genet. 1992;42:667-670
10. Noonan KJ, LeyesM,Forriol F, CaaDell J. Distraction osteogenesis of the lower extremity with use of monolateral external fixation. A study of two hundred and sixty-one femora and tibiae. J Bone Joint Surg Am. 1998;80:793-806
11. Krejci P, Murakami S, Prochazkova J, et al. NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells. J Biol Chem. 2010;285:20644-20653
12. Jonquoy A, Mugniery E, Benoist-Lasselin C, et al. A novel tyrosine kinase inhibitor restores chondrocyte differentiation and promotes bone growth in a gain-of-function Fgfr3 mouse moDel. Hum Mol Genet. 2012;21:841-851
13. Jin M, Yu Y, Qi H, et al. A novel FGFR3-binding peptiDe inhibits FGFR3 signaling and reverses the lethal phenotype of mice mimicking human thanatophoric dysplasia. Hum Mol Genet. 2012;21: 5443-5455
14. Yasoda A, Komatsu Y, Chusho H, et al. Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-DepenDent pathway. Nat Med. 2004;10:80-86
15. Yasoda A, Kitamura H, Fujii T, et al. Systemic administration of C-type natriuretic peptiDe as a novel therapeutic strategy for skeletal dysplasias. Endocrinology. 2009;150:3138-3144
16. Lorget F, Kaci N, Peng J, et al. Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse moDel recapitulating achondroplasia. Am J Hum Genet. 2012;91:1108-1114
17. Yamashita A, Morioka M, Kishi H, et al. Statin treatment rescues FGFR3 skeletal dysplasia phenotypes. Nature. 2014;513:507-511
18. Matsushita M, Kitoh H, Ohkawara B, et al. Meclozine facilitates proliferation and differentiation of chondrocytes by attenuating abnormally activated FGFR3 signaling in achondroplasia. PLoS One. 2013;8:e81569-e81569
19. Naski MC, Colvin JS, Coffin JD, Ornitz DM. Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3. Development. 1998;125:4977-4988
20. Mori K, Suenaga Y, Toriwaki J. Fast software-based volume renDering using multimedia instructions on PC platforms and its application to virtual endoscopy. Proc SPIE. 2003;5031:111-122
21. Wallin J, Wilting J, Koseki H, Fritsch R, Christ B, Balling R. The role of Pax-1 in axial skeleton Development. Development. 1994;120: 1109-1121
22. Wang Z, Lee B, Pearce D, et al. Meclizine metabolism and pharmacokinetics: Formulation on its absorption. J Clin Pharmacol. 2012;52:1343-1349
23. Kitoh H, Kitakoji T, Tsuchiya H, Katoh M, Ishiguro N. Distraction osteogenesis of the lower extremity in patients with achondroplasia/ hypochondroplasia treated with transplantation of culture-expanDed bone marrow cells and platelet-rich plasma. J Pediatr Orthop B. 2007;27:629-634
24. Matsushita T, Wilcox WR, Chan YYet al. FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway. Hum Mol Genet. 2009;18:227-240.